Creative Biolabs is a world-leading service provider of application-specific antibody development. Here, we introduce our in vitro diagnostic (IVD) antibody development and immunoassay development services targeting the NGAL marker. We are confident that our commitment to science and research will enable us to offer you the best products and services.

Neutrophil Gelatinase-associated Lipocalin (NGAL)

Neutrophil gelatinase-associated lipocalin (NGAL), also known as Lipocalin-2 (LCN2), migration stimulating factor inhibitor (MSFI) or human neutrophil lipocalin (HNL), is a 198 amino acid glycoprotein encoded by NGAL gene located on the chromosome locus 3p11. NGAL presents various functions in human body. It functions as an iron transporting protein during nephrogenesis. And NGAL can regulate the overall balance of proximal tubule cell fate toward cell survival after ischemic injury. Moreover, NGAL can also enhance the epithelial phenotype through improving tubule cell apoptosis and strengthening tubule cell proliferation. Besides, some studies have shown that NGAL may also regulate downstream gene expression involved in cancer metastasis, such as breast cancer, colorectal cancer.

Overview of Potential Effects of NGAL on Cellular Growth Fig.1 Overview of Potential Effects of NGAL on Cellular Growth (Chappell W H., 2012)

NGAL Marker of Acute Kidney Injury (AKI)

Acute kidney injury (AKI) is a sudden or rapid decline of kidney function that develops within a few hours and a few days. Usually, kidney functions as a cleaner that remove fluid, waste and toxin from circulation. But AKI patients don’t have the normal kidney functions, which leads to severe clinical signs. So, monitoring the progress of AKI in the early period is very important, which will help to AKI treatment and reduce further kidney injury.

Based on the differential expression of NGAL in disease states, lots of investigations suggest that NGAL levels in urine or plasma can be regarded as a biomarker in the early diagnosis of acute kidney injury (AKI). Under normal conditions, NGAL levels are relatively low in urine and plasma. However, NGAL levels in kidney injury patients are rapidly increased from basal levels to reach diagnostic levels in a short time, as much as 24 h or more before a detectable increase of serum creatinine. Recent studies also suggest that measure urinary NGAL levels can also be used to predict the progression of chronic kidney diseases, assess therapeutic prognosis in kidney injury, and screen candidate drug applied to the treatment of AKI.

Nature and source of NGAL in plasma and urine during AKI Fig. 2 Nature and source of NGAL in plasma and urine during AKI (Martensson J., 2014)

IVD Antibody Development Services for NGAL Marker

IVD antibodies have been widely used in the diagnosis of numerous diseases. Antibody-based immunoassays are the most generally used diagnostic assays for the detection of biomolecules. With advanced technology and professional scientists, Creative Biolabs is capable of offering a full range of IVD antibody development services against various markers to global customers. Besides, Creative Biolabs provides one-stop diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, validation, and kit production. Contact us to learn more about what we offer and how to get started on your next project.

References

  1. Chappell W H., (2012). “Montalto G, et al. Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity”. Oncotarget, 3(10):1236-1245.
  2. Martensson J.,(2014). “The rise and fall of NGAL in acute kidney injury”. Blood Purification, 37(4):304-310.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2020 Creative Biolabs.